KRAS and neoplasm: After the tumor volume reached around 80~100 mm3, 100 μg HLA-A2/KRAS G12V-CD3 BiTE was given intravenously every 2 days, 1×107 T cells and 200 μg DSPE-PEG-iRGD every 4 days (Figure 6A).